reason report
soft hiv filgotinib outlook critic pt
bottom line gilead ep beat benefit slower
gener eros one-tim benefit ep in-lin
ex benefit although biktarvi continu launch well
overal hiv result somewhat disappoint hiv
franchis continu grow y/i gilead domin
market posit provid solid defens competitor
becom activ aggress viiv
consider uncertainti compani direct capit
alloc prioriti strategi find hard get excit
stock upsid least sequenc approv
variou jak inhibitor clarif gilead
invest ambit commerci highli
competit rheumatoid arthriti categori base quarter
result manag comment guidanc
decreas revenu estim longer term
forecast increas base biktarvi pro forma ep
estim decreas base increas sg
expens like increas well increas
year base chang target price remain
reiter market perform rate compani
though biktarvi strongest launch date hiv
cannib gilead medicin steeper declin
ex-u hiv sale limit upsid hiv estim non-
hiv product overhang filgotinib inhibitor file
rheumatoid arthriti lift investor like remain
skeptic gilead abil compet crowd therapeut categori
breadth label portfolio histor signific
advantag pipelin gilead second shot build
nonalcohol steatohepat nash treatment portfolio
present combin data later year three asset
combin though result could gener signific investor
interest suffici evid effect
molecul recommend stock ahead catalyst
guidanc increas appear captur one-tim item
increas product sale guidanc roughli similar
one-tim sale benefit surpris quarter letairi
without gener eros quarter decreas
revenu estim reflect lower near term hiv
estim increas estim longer term
also decreas pro forma ep estim
compani inform svb leerink llc research
revenu mm non-gaap ep ex stock option expens
averag price-to-earnings large-cap revenu
multipl slower-growth medic co
sum part exist franchis
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
increas term despit increas expect
sg expens base chang peer compani multipl
reiter price target market perform rate
rate gilead stock market perform price target gilead matur
gener biotech compani search next wave innov growth
compani leader hiv medicin busi increas alreadi domin market
share indic expect hiv product sale grow peak
expect signific eros taf/descovi franchis gilead
also built lead posit hepat medicin busi continu declin
headi peak two franchis believ worth compani
recent share price rest compani pipelin consist mainli late life cycl
product ranexa letairi commerci disappoint zydelig
yescarta kinas inhibitor filgotinib near term compani outlook
much depend result pivot trial nash medicin immedi
inhibitor firsocostat trial disappoint compani stock price could suffer
multipl compress expect compani revenu remain rang
next year earn hover rang level stock seem like
enjoy multipl line ex-growth matur biopharmaceut busi
view upsid downsid risk come compani busi
develop capit alloc choic opportun
in-lin quarterli sale stretch beat one-tim benefit delay loe effect
total revenu consensu estim
howev investor disappoint beat driven less eros legaci
respiratori letairi hcv asset boost one-tim sale claw-back
spread across eu portfolio overal gilead main hiv franchis miss consensu
despit newly-launch biktarvi consensu beat impress quarterli
total hiv/hbv product sale consensu
estim miss driven rapid eros gilead legaci
tenofovir disoproxil tdf -base hiv product newer tenofovir alafenamid taf -base
hiv product howev newest taf product biktarvi also steal share
taf-bas product previous expect instanc odefsey genvoya declin
sequenti alreadi weak descovi increas sequenti two
product plu descovi miss consensu compound product mix issu
legaci hiv product post strong row sale due one-tim claw-back benefit eu
without benefit total row hiv sale would declin sequenti hiv miss
would larger miss
total hcv sale consensu estim also
benefit one-tim eu claw-back without benefit gilead hcv sale
would miss consensu
sale non-antivir product mix ranexa disappear due gener
competit letairi came doubl vs consensu due delay
gener eros appear sustain yescarta sale
consensu
total without one-tim eu claw-back benefit calcul gilead would report
in-lin sale compar consensu
one-tim also off-set high sg tax ep beat
gross margin consensu gross margin increas
product mix continu shift newer hiv product bear
signific royalti non-gaap consensu non-gaap
sg consensu sg grown y/i total revenu
increas gilead attribut increas sell cost expans gilead
busi japan china suggest see expens would continu
increas rather stabil declin total gilead expens
consensu estim gilead oper margin line last
year quarter effect tax rate higher previou
quarter year gilead still guid full-year tax rate combin non-
dilut ep consensu line estim gilead
attribut ep eu claw-back benefit mean compani would
report in-lin quarter without one-tim item ep would declin
prior period share repurchas
top-lin guidanc increas modestli primarili captur one-tim item
gilead increas top-lin financi guidanc reiter prior expens
guidanc manag expect product sale
boost appear captur one-tim eu claw-back benefit extra
quarter un-erod letairi revenu reflect addit strength core hiv
busi new rang bracket consensu gilead reiter expect
product gross margin non-gaap sg
expens bracket consensu final manag
reiter expect effect tax rate line recent consensu
estim expens like increas back half year compani
prepar expens inflammatori diseas launch sign new manag
interest appetit signific restructur either sg despit
catalyst path domin descovi prep approv filgotinib file earli nash
gilead file descovi pre-exposur prophylaxi prep success non-inferior phase
trial see note prioriti review voucher expect approv like
decemb believ fda schedul advisori committe review snda
august call manag suggest meet call
discuss breadth label descovi compani seek indic
adolesc adult phase studi conduct men sex
men gilead also state meet could use gather key opinion leader
effort increas awar prep high-risk individu estim
cdc prophylact therapi believ advisori committe rigor
discuss merit studi intend label breadth label hard
believ panel would vote approv broad label prophylact use given
total safeti data collect taf date
filgotinib investor await word fda file accept follow
pre-nda meet fda discuss latest phase data earlier month gilead
partner galapago announc intent file filgotinib rheumatoid arthriti year-end
compani investor previous expect file would delay testicular
toxic manta studi complet next year per discuss gilead fda
agre allow gilead file current blind manta trial data packag full
manta data drug approv phase iv post approv studi base
new timelin drug could approv earli fda flexibl
examin phase data suggest us filgotinib inde approv without issu
import clinic data gilead stock year anticip nonalcohol
steatohepat nash combin data american associ studi liver
diseas aasld meet novemb phase ii atla data show differ
combin three gilead nash medicin firsocostat inhibitor cilofexor fxr
agonist selonsertib inhibitor endpoint studi safeti proport
patient achiev improv fibrosi without worsen nash week
provid materi proof concept success combin valu
nash fallen gilead stock phase failur monotherapi selonsertib
posit result novemb like draw signific investor interest
base result quarter manag commentari well high-level
analysi current trend hiv market decreas revenu estim
increas estim forecast gilead total
revenu increas flat truvada goe gener
grow within busi unit decreas total hcv
revenu forecast later estim unchang decreas
total hiv revenu forecast increas estim longer term biggest
chang within hiv biktarvi increas form
revenu estim consensu
increas forecast oper expens year primarili account
higher plan sg new product launch ebit margin forecast
percentag point lower result pro forma ep estim
decreas increas longer term ep estim
consensu base chang
revenu forecast ep estim cash flow reiter price target gilead
maintain market perform rate gilead stock
price target inc base averag four approach
believ reason basi valu stock today approach trough
price earn multipl larg cap slow-growth medic product busi long term
revenu multipl larg cap medic product stock slow growth outlook sum
part valuat exist franchis discount cash flow dcf use trough consensu
forward earn multipl slow-growth medic product stock celg
appli ep estim gilead give price
altern appli slow-grow large-cap biopharma product
celg rhhbi nv revenu multipl revenu estim deriv
impli valu impli one-year price target use sum part valuat
exist franchis get price consist primarili price
compani hiv franchis hcv product lastli dcf use forecast free
cash flow appli growth rate termin cash flow forecast
discount valu back present wacc give present valu
averag four approach price target
risk view outlook valuat gilead includ major chang label
price reimburs coverag compani exist hiv hcv product emerg
aggress price discount rebat valu eros hiv hcv
categori current forecast failur compani princip pipelin
asset selonsertib nash filgotinib ra ibd advanc develop
commerci opportun better perform valu expect includ
delay limit develop profil adopt competit hiv product
success develop underappreci element compani portfolio gs-
fxr agonist inhibitor follow-on car-t indic stronger-than-
expect convers current hiv patient gilead next gener taf-bas hiv treatment
royalti contract revenu
non-gaap cost good sold
share count period basic
guidanc
dilut ep impact relat acqusit
stock-bas compens
svb leerink llc research compani file zack factset consensu
svb leerink llc research compani file zack factset consensu
late stage pipelin program includ
late stage pipelin program exclud
brand
type event
event trial detail
date known
up/down
expect
phase ii result registr
phase result
file fda regulatori approv mcl
phase ii testicular safeti filgotinib result
svb leerink llc research compani file
million
symtuza darunavir/c/f-taf royalti
symtuza darunavir/c/f-taf royalti
svb leerink llc research compani file
million
sale incl emori amort
 total revenu
sg total revenu
profit share total revenu
svb leerink llc research compani file
analysi stock price svb leerink target
method trough price earn multipl larg cap slow growth biopharma compani
trough larg cap valu healthcar stock multipl ep celg
impli valuat ep
number period
equiti
method revenu multipl slow growth outlook larg cap biopharma stock appli
svb leerink revenu estim gilead
comp ex growth larg cap revenu multipl
impli valu gilead revenu
share outstand gilead
impli year price base revenu
method part valuat exist franchis kite
method dcf base current late stage pipelin product declin flow post
wacc growth termin period
present valu late stage market product flow termin valu
net debt
present valu late stage market product flow
averag method
svb leerink llc partner research compani file factset
